JERSEY, Channel Islands , March 07, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company’s Chief Financial Officer, Chris Lindop , will present at the Cowen and Company 39 th Annual Health Care Conference on Monday, March
JERSEY, Channel Islands , Feb. 19, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company will host an Investor Day on Monday, March 4, 2019 from 1:00pm – 3:00pm ET , in New York, NY .
JERSEY, Channel Islands , Feb. 15, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that today announced that the Company’s Chief Executive Officer, Franz Walt , will present at the 8 th Annual SVB Leerink Global Healthcare Conference
Development data provides positive results for extended IH microarray panel Field trial for initial Serological Disease microarray panel has commenced Reagent revenue growth of 15% in the quarter and 12% year to date JERSEY, Channel Islands , Jan. 31, 2019 (GLOBE NEWSWIRE) -- Quotient Limited
JERSEY, Channel Islands , Jan. 17, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal third quarter ended December 31, 2018 , will be released before market open on Thursday, January 31, 2019 .
JERSEY, Channel Islands , Dec. 11, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today reported receipt of the formal ISO 13485:2016 certification for its state of the art MosaiQ™ multiplexing microarray manufacturing facility
JERSEY, Channel Islands , Dec. 11, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT) (the Company), a commercial-stage diagnostics company, today announced the closing of its previously announced underwritten public offering of 10,615,385 ordinary shares at a price to the public of $6.50 per
JERSEY, Channel Islands , Dec. 06, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT) (the Company), a commercial-stage diagnostics company, today announced the pricing of its previously announced underwritten public offering of 9,230,770 ordinary shares at a price to the public of $6.50 per
JERSEY, Channel Islands , Dec. 06, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT) (the Company), a commercial-stage diagnostics company, today announced the Company intends to commence an underwritten public offering of its ordinary shares. All of the ordinary shares to be sold in the
JERSEY, Channel Islands , Dec. 04, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today announced the receipt of consents from the holders of its Senior Secured Notes (the Notes) to certain amendments (the Proposed Amendments) to the
